Literature DB >> 16644287

Analysis of human sera that are polyreactive in an addressable laser bead immunoassay.

Marvin J Fritzler1, Fatemeh Behmanesh, Mark L Fritzler.   

Abstract

BACKGROUND: Following the introduction of addressable laser bead immunoassays (ALBIA) into our clinical laboratory, it was noted that certain sera would exhibit reactivity to numerous antigens in the array. To further understand the nature of this reactivity, we analyzed the reactivity of sequential sera that were identified over a 1 year period.
METHODS: Sera that demonstrated reactivity to 6 or more of the 8 antigens in an ALBIA kit (QuantaPlex 8: chromatin, Sm, RNP, Scl-70, ribosomal P protein, SS-A/Ro, SS-B/La, Jo-1) were tested for autoantibodies by indirect immunofluorescence (IIF) on HEp-2 cell substrates, for IgG, IgM and IgA rheumatoid factor, chromatin and ribosomal P protein by ELISA and by LINE immunoassay (LIA) and immunoblotting (IB).
RESULTS: In one calendar year, 40/4096 (0.8%) sera analyzed in a routine clinical laboratory setting demonstrated reactivity to 6 or more antigens in the QuantaPlex 8 kits. There was no common IIF pattern that could be attributed to the polyreactive sera. There was no apparent correlation of polyreactivity with IIF titers, indeed, 4/40 (10%) sera had a negative ANA at the screening dilution of 1/160. When subjected to IB, LIA and ELISA, polyreactivity to three or more antigens was confirmed for 12/40 (30%) of sera while 8/40 (20%) had reactivity to 1-2 antigens and 20 (50%) did not react with any antigens in these assays. Overall agreement of positive or negative tests between the ALBIA and IB, LIA and ELISA was 75% for chromatin, 50% for SS-A, 27.5% for Sm, 25% for Rib-P, 22.5% for RNP, 20% for Scl-70, 15% for Jo-1 and 7.5% for SS-B. 17/40 (42.5%) had a positive IgM, IgG or IgA rheumatoid factor, and 12/40 (30%) had all three isotype rheumatoid factors.
CONCLUSIONS: On average, the agreement between ALBIA and other assays in this study of polyreactive sera was 30%. Approximately, one-half of sera that demonstrate reactivity to multiple autoantigens in a commercial ALBIA were confirmed to have reactivity to at least one autoantigen in another diagnostic assay and 30% could be regarded as polyreactive. Other sera, some of which had rheumatoid factor, appeared to have high background binding without demonstrating specific binding to any of the cognate antigens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644287     DOI: 10.1016/j.clim.2006.03.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  7 in total

1.  Prevention of assay interference in infectious-disease serology tests done on the liaison platform.

Authors:  Mario Berth; Eugene Bosmans
Journal:  Clin Vaccine Immunol       Date:  2008-03-12

2.  Clinical and serological features of patients with autoantibodies to GW/P bodies.

Authors:  Rahima A Bhanji; Theophany Eystathioy; Edward K L Chan; Donald B Bloch; Marvin J Fritzler
Journal:  Clin Immunol       Date:  2007-09-17       Impact factor: 3.969

3.  Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies.

Authors:  Laurent Drouot; Yves Allenbach; Fabienne Jouen; Jean-Luc Charuel; Jérémie Martinet; Alain Meyer; Olivier Hinschberger; Brigitte Bader-Meunier; Isabelle Kone-Paut; Emmanuelle Campana-Salort; Bruno Eymard; Anne Tournadre; Lucile Musset; Jean Sibilia; Isabelle Marie; Olivier Benveniste; Olivier Boyer
Journal:  Arthritis Res Ther       Date:  2014-02-03       Impact factor: 5.156

Review 4.  Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.

Authors:  Michael Mahler; Pier-Luigi Meroni; Xavier Bossuyt; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-27       Impact factor: 4.818

5.  Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients.

Authors:  Eduardo Bonilla; Lisa Francis; Fatme Allam; Meribeth Ogrinc; Hom Neupane; Paul E Phillips; Andras Perl
Journal:  Clin Immunol       Date:  2007-05-21       Impact factor: 3.969

6.  Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes.

Authors:  Martial Koenig; Marvin J Fritzler; Ira N Targoff; Yves Troyanov; Jean-Luc Senécal
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

7.  Highlights on novel technologies for the detection of antibodies to Ro60, Ro52, and SS-B.

Authors:  M Infantino; C Bentow; A Seaman; M Benucci; F Atzeni; P Sarzi-Puttini; B Olivito; F Meacci; M Manfredi; M Mahler
Journal:  Clin Dev Immunol       Date:  2013-11-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.